NIH R01 · 2025
IL-1R1 in Endothelial-to-Mesenchymal Activation
PROJECT SUMMARY: Endothelial-to-mesenchymal transition (EndMT) has been detected in atherosclerosis, and the extent of EndMT observed in the human plaques strongly correlates with the severity of the disease, implying clinical relevance of EndMT in the pathogenesis of atherosclerosis. Both disturbed blood flow (d-flow) and interleukin-1 signaling (IL-1) have been implicated in EndMT formation. The signaling pathway that links d-flow and EndMT is still unclear. Moreover, IL-1 as a therapeutic target has already been tested and the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) assessed the therapeutic effect of the anti-IL-1β antibody in patients after myocardial infarction…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.